Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 25.1% in January
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 25.1% in January
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Get Rating) saw a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 5,590,000 shares, a growth of 25.1% from the December 31st total of 4,470,000 shares. Approximately 14.0% of the company's stock are sold short. Based on an average trading volume of 533,200 shares, the short-interest ratio is presently 10.5 days.
第一天生物製藥公司(納斯達克：曙光評級)看到空頭股數在一月份有很大的增長。截至1月15日，空頭股數共有559萬股，比12月31日的447萬股增長了25.1%。該公司約14.0%的股票被賣空。以平均成交量53.32萬股計算，目前短息比率為10.5天。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
DAWN has been the topic of a number of research reports. Bank of America initiated coverage on Day One Biopharmaceuticals in a research report on Thursday, December 1st. They set a "buy" rating and a $34.00 target price on the stock. Piper Sandler upped their price objective on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an "overweight" rating in a report on Sunday, January 8th. HC Wainwright raised their price objective on shares of Day One Biopharmaceuticals from $35.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, January 9th. The Goldman Sachs Group boosted their target price on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the stock a "buy" rating in a research report on Monday, January 9th. Finally, Needham & Company LLC assumed coverage on shares of Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They issued a "buy" rating and a $40.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $43.50.
黎明已經成為許多研究報告的主題。美國銀行在12月1日星期四的一份研究報告中開始了對第一天生物製藥的保險。他們為該股設定了“買入”評級和34.00美元的目標價。派珀·桑德勒在1月8日週日的一份報告中將第一天生物製藥公司的股票目標價從40.00美元上調至45.00美元，並給予該股“增持”評級。1月9日，週一，HC Wainwright在一份研究報告中將第一天生物製藥公司的股票目標價從35.00美元上調至45.00美元，並給予該公司“買入”評級。1月9日，高盛夫婦在一份研究報告中將第一天生物製藥的目標價從45.00美元上調至62.00美元，並給予該股“買入”評級。最後，Needham&Company LLC在12月14日星期三的一份研究報告中對第一天生物製藥公司的股票進行了報道。他們對該股給予了“買入”評級和40.00美元的目標價。根據MarketBeat.com的數據，六位投資分析師對該股的評級為買入，目前該股的普遍評級為買入，平均目標價為43.50美元。
Day One Biopharmaceuticals Price Performance
首日生物藥品價格表現
NASDAQ:DAWN traded down $0.09 during trading hours on Friday, hitting $21.45. 263,007 shares of the company traded hands, compared to its average volume of 641,030. Day One Biopharmaceuticals has a one year low of $5.44 and a one year high of $28.35. The firm's 50-day simple moving average is $21.31 and its 200-day simple moving average is $21.15.
納斯達克：曙光在週五的交易時間裏下跌了0.09美元，達到21.45美元。該公司有263,007股易手，而其平均成交量為641,030股。第一天生物製藥的一年低點為5.44美元，一年高位為28.35美元。該公司的50日簡單移動均線切入位為21.31美元，200日簡單移動均線切入位為21.15美元。
Insider Activity at Day One Biopharmaceuticals
生物製藥公司上市第一天的內部活動
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm's stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total value of $228,600.00. Following the completion of the sale, the insider now directly owns 1,250,148 shares in the company, valued at $28,578,383.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction dated Tuesday, January 10th. The shares were sold at an average price of $22.86, for a total transaction of $228,600.00. Following the transaction, the insider now owns 1,250,148 shares of the company's stock, valued at approximately $28,578,383.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Julie Papanek Grant sold 5,000 shares of the firm's stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $20.04, for a total value of $100,200.00. Following the completion of the sale, the director now owns 424,358 shares of the company's stock, valued at $8,504,134.32. The disclosure for this sale can be found here. Insiders have sold 151,678 shares of company stock worth $3,189,287 in the last quarter. Company insiders own 8.70% of the company's stock.
在第一天的其他生物製藥新聞中，內部人士塞繆爾·C·布萊克曼在1月10日星期二的一筆交易中出售了10,000股該公司的股票。這些股票的平均價格為22.86美元，總價值為228,600.00美元。出售完成後，這位內部人士現在直接擁有該公司1,250,148股，價值28,578,383.28美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在美國證券交易委員會網站。在其他新聞方面，內部人士塞繆爾·C·布萊克曼在1月10日星期二的交易中出售了10,000股該股。這些股票以22.86美元的平均價格出售，總成交金額為228,600.00美元。交易完成後，這位內部人士現在擁有1,250,148股該公司股票，價值約28,578,383.28美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過美國證券交易委員會網站。此外，董事朱莉·帕帕內克·格蘭特在一筆日期為11月1日星期二的交易中出售了5,000股該公司股票。這些股票的平均價格為20.04美元，總價值為100,200.00美元。出售完成後，董事現在擁有424,358股該公司的股票，價值8,504,134.32美元。關於這次銷售的披露可以找到這裏。上個季度，內部人士出售了151,678股公司股票，價值3,189,287美元。公司內部人士持有該公司8.70%的股份。
Hedge Funds Weigh In On Day One Biopharmaceuticals
對衝基金在生物製藥上市首日發表意見
Hedge funds have recently modified their holdings of the company. Atlas Venture Life Science Advisors LLC increased its position in shares of Day One Biopharmaceuticals by 9.3% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 8,968,305 shares of the company's stock valued at $160,533,000 after acquiring an additional 766,667 shares during the last quarter. FMR LLC increased its position in shares of Day One Biopharmaceuticals by 163.1% during the 2nd quarter. FMR LLC now owns 6,826,574 shares of the company's stock valued at $122,196,000 after purchasing an additional 4,232,055 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Day One Biopharmaceuticals by 68.3% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company's stock worth $62,867,000 after purchasing an additional 1,425,674 shares during the period. BlackRock Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 29.5% in the 3rd quarter. BlackRock Inc. now owns 2,541,235 shares of the company's stock worth $50,901,000 after buying an additional 578,511 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in Day One Biopharmaceuticals by 59.8% during the second quarter. Franklin Resources Inc. now owns 2,465,380 shares of the company's stock valued at $44,130,000 after buying an additional 922,521 shares during the period. Institutional investors own 86.08% of the company's stock.
對衝基金最近調整了對該公司的持股。Atlas Venture Life Science Advisors LLC在第二季度將其在第一天生物製藥公司的股票頭寸增加了9.3%。Atlas Venture Life Science Advisors LLC在上個季度增持了766,667股後，現在擁有該公司8,968,305股股票，價值160,533,000美元。FMR LLC在第二季度將其在第一天生物製藥公司的股票頭寸增加了163.1%。FMR LLC在上個季度額外購買了4,232,055股後，現在擁有6,826,574股該公司股票，價值122,196,000美元。Deerfield Management Company L.P.Series C在第二季度將其在第一天生物製藥公司的股份增加了68.3%。Deerfield Management Company L.P.C系列現在擁有該公司3,512,123股股票，價值62,867,000美元，在此期間又購買了1,425,674股。貝萊德股份有限公司在第三季度增持了第一天生物製藥公司的股票29.5%。貝萊德股份有限公司在上季度增持了578,511股後，目前持有該公司2,541,235股股票，價值50,901,000美元。最後，富蘭克林資源公司在第二季度將其在第一天生物製藥公司的頭寸增加了59.8%。富蘭克林資源公司目前持有該公司2,465,380股股票，價值44,130,000美元，在此期間又購買了922,521股。機構投資者持有該公司86.08%的股票。
Day One Biopharmaceuticals Company Profile
第一天生物製藥公司簡介
(Get Rating)
(獲取評級)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
第一天生物製藥公司是一家臨牀階段的生物製藥公司，為基因定義的癌症患者開發和商業化靶向療法。它的主要候選產品是DAY101，這是一種口服II型泛快速加速纖維肉瘤激酶抑制劑，目前正處於兒童復發/進展性低級別膠質瘤患者的II期臨牀試驗中。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 在第一天生物製藥(黎明)獲得一份免費的StockNews.com研究報告
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升，提振銷售觀點
- KLA公司：在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受《生物製藥日報》第一天的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對第一天生物製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。